首页 › 肝癌（肝细胞癌） › 宾夕法尼亚州 › Pittsburgh
Pittsburgh PA 肝癌（肝细胞癌）临床试验
15项针对 肝癌（肝细胞癌）的研究正在 Pittsburgh及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Phase 1 Study of the Safety and Tolerability of CTX-10726
招募中1 期
- UPMC Hillman Cancer Center, Pittsburgh
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
招募中1 期
- Exelixis Clinical Site #32, Pittsburgh
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
招募中1/2 期
- Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh
Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
招募中1/2 期
- UPMC Hillman Cancer Center, Pittsburgh
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
招募中3 期
- Research Site, Pittsburgh
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
招募中1/2 期
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
FOG-001 in Locally Advanced or Metastatic Solid Tumors
招募中1/2 期
- University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh
Molecular Basis of Pediatric Liver Cancer
招募中观察性研究
- UPMC Children's Hospital of Pittsburgh, Pittsburgh
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
招募中2 期
- Allegheny General Hospital, Pittsburgh
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
招募中2 期
- UPMC Hillman Cancer Center, Pittsburgh
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
招募中1 期
- Clinical Trial Site, Pittsburgh
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
招募中2 期
- UPMC Hillman Cancer Center, Pittsburgh
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
招募中2 期
- UPMC Hillman Cancer Center, Pittsburgh
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
招募中1/2 期
- UPMC Hillman Cancer Center, Pittsburgh
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
招募中2 期
- UPMC Hillman Cancer Center, Pittsburgh
其他城市的 肝癌（肝细胞癌）试验
- Houston, TX31 项研究
- New York City, NY24 项研究
- Dallas, TX19 项研究
- Los Angeles, CA19 项研究
- Boston, MA18 项研究
- Cleveland, OH18 项研究
- Chicago, IL16 项研究
- Philadelphia, PA16 项研究
- San Francisco, CA14 项研究
- Orange, CA14 项研究
- Jacksonville, FL14 项研究
- San Antonio, TX13 项研究
Pittsburgh的其他研究
- 非小细胞肺癌48 项研究
- 癌症（所有类型）41 项研究
- 乳腺癌39 项研究
- 结直肠癌32 项研究
- 转移性癌症31 项研究
- 黑色素瘤31 项研究
- 卵巢癌30 项研究
- 子宫内膜癌23 项研究
- 前列腺癌23 项研究
- 肺癌23 项研究
- 头颈鳞状细胞癌22 项研究
- 卒中22 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。